What Is 17β-hydroxysteroid dehydrogenase III

Overview

17β-hydroxysteroid dehydrogenase type III (HSD17B3) is a critical enzyme in steroid hormone biosynthesis, primarily involved in male sexual development. It plays a central role in converting weak androgens into more potent forms, specifically transforming androstenedione into testosterone.

This enzyme is essential during fetal development and puberty, ensuring proper masculinization in genetic males. Deficiencies or mutations in HSD17B3 can lead to disorders of sex development (DSD), particularly in 46,XY individuals who may present with ambiguous genitalia or female-typical external anatomy.

• Chromosome 9q22: The HSD17B3 gene is located on the long arm of chromosome 9 at position q22, a region associated with several endocrine-related genes.
• First cloned in 1994: Researchers successfully isolated and sequenced the HSD17B3 gene in 1994, enabling further study of its role in androgen synthesis.
• Testosterone biosynthesis: HSD17B3 catalyzes the NADPH-dependent reduction of androstenedione to testosterone, a reaction critical for male phenotypic development.
• High substrate affinity: The enzyme exhibits a Km of approximately 0.2 μM for androstenedione, indicating strong binding efficiency and high catalytic activity.
• Tissue-specific expression: HSD17B3 is predominantly expressed in the Leydig cells of the testes and, to a lesser extent, in the adrenal cortex, limiting its activity to key steroidogenic tissues.

How It Works

Understanding the biochemical mechanism of HSD17B3 requires examining its enzymatic structure, cofactor requirements, and interaction with substrates. Each component plays a role in ensuring efficient testosterone production during critical developmental windows.

• Enzyme Class: HSD17B3 belongs to the short-chain dehydrogenase/reductase (SDR) superfamily, characterized by a conserved Rossmann fold and NADPH dependency, which supports redox reactions in steroid metabolism.
• Cofactor NADPH: The reaction catalyzed by HSD17B3 requires NADPH as a cofactor, providing the reducing equivalents needed to convert the keto group at C17 of androstenedione to a hydroxyl group.
• Substrate Specificity: HSD17B3 shows high specificity for androstenedione, with minimal activity toward estrone or other 17-ketosteroids, distinguishing it from other HSD17B isoforms.
• pH Optimum: The enzyme functions optimally at a pH of 9.5, which is unusually high and suggests a specialized microenvironment within Leydig cells for maximal activity.
• Gene Structure: The HSD17B3 gene spans approximately 70 kb and contains 11 exons, with mutations in exons 4–6 commonly linked to enzyme deficiency.
• Protein Size: The encoded protein consists of 301 amino acids and has a molecular weight of about 33 kDa, forming a functional homodimer in its active state.

Key Comparison

This comparison highlights the distinct roles of HSD17B isoforms across tissues. While HSD17B3 is pivotal for male development, other isoforms regulate estrogen activity or inactivate steroids, demonstrating functional diversity within the enzyme family.

Key Facts

Scientific and clinical research has uncovered several critical facts about HSD17B3, including genetic, biochemical, and epidemiological data that underscore its importance in human health.

• Prevalence in Turkey: In certain regions of Turkey, HSD17B3 deficiency accounts for up to 50% of 46,XY DSD cases due to a founder mutation (p.Ala283Val), indicating a regional genetic hotspot.
• Age of diagnosis: Most cases are diagnosed between 1–5 years of age, often after parents notice atypical genitalia or delayed puberty in genetic males.
• Incidence rate: The estimated incidence of HSD17B3 deficiency is 1 in 150,000 births, though it may be underdiagnosed in populations without genetic screening.
• Hormonal ratio: Patients often exhibit an elevated androstenedione-to-testosterone ratio of >3:1, a key diagnostic marker used in clinical endocrinology.
• Gene mutations: Over 30 pathogenic variants in HSD17B3 have been documented in the Human Gene Mutation Database, including missense, nonsense, and splice-site mutations.
• Pubertal virilization: Some individuals experience partial virilization at puberty due to increased gonadotropins, with testosterone levels rising to 30–50% of normal.

Why It Matters

Understanding HSD17B3 is vital for diagnosing and managing disorders of sex development, guiding clinical decisions, hormone replacement, and psychosocial support. Its role in testosterone synthesis makes it a key target in endocrinology and reproductive medicine.

• Diagnostic accuracy: Identifying HSD17B3 mutations improves diagnostic precision, reducing misclassification of 46,XY individuals as female at birth.
• Genetic counseling: Families benefit from carrier testing and recurrence risk assessment, especially in populations with high mutation prevalence like southern Turkey.
• Hormone therapy: Early testosterone supplementation can promote normal male development, with treatment often starting at 3–6 months of age.
• Surgical decisions: Accurate diagnosis prevents unnecessary feminizing genitoplasty in infants later identified as male due to pubertal virilization.
• Research implications: Studying HSD17B3 aids in understanding steroidogenesis and may lead to targeted therapies for androgen-related conditions like infertility.